Small Airway Function Measured Using Forced Expiratory Flow Between 25% and 75% of Vital Capacity and Its Relationship to Airflow Limitation in Symptomatic Ever-smokers: a Cross-sectional Study
Overview
Affiliations
Background: Chronic obstructive pulmonary disease (COPD) is diagnosed and its severity graded by traditional spirometric parameters (forced expiratory volume in 1 s (FEV)/forced vital capacity (FVC) and FEV, respectively) but these parameters are considered insensitive for identifying early pathology. Measures of small airway function, including forced expiratory flow between 25% and 75% of vital capacity (FEF), may be more valuable in the earliest phases of COPD. This study aimed to determine the prevalence of low FEF in ever-smokers with and without airflow limitation (AL) and to determine whether FEF relates to AL severity.
Method: A retrospective analysis of lung function data of 1458 ever-smokers suspected clinically of having COPD. Low FEF was defined by z-score<-0.8345 and AL was defined by FEV/FVC z-scores<-1.645. The severity of AL was evaluated using FEV z-scores. Participants were placed into three groups: normal FEF/ no AL (normal FEF/AL-); low FEF/ no AL (low FEF/AL-) and low FEF/ AL (low FEF/AL+).
Results: Low FEF was present in 99.9% of patients with AL, and 50% of those without AL. Patients in the low FEF/AL- group had lower spirometric measures (including FEV FEF/FVC and FEV/FVC) than those in the normal FEF/AL- group. FEF decreased with AL severity. A logistic regression model demonstrated that in the absence of AL, the presence of low FEF was associated with lower FEV and FEV/FVC even when smoking history was accounted for.
Conclusions: Low FEF is a physiological trait in patients with conventional spirometric AL and likely reflects early evidence of impairment in the small airways when spirometry is within the 'normal range'. FEF likely identifies a group of patients with early evidence of pathological lung damage who warrant careful monitoring and reinforced early intervention to abrogate further lung injury.
Hu J, Fan Y, Luo R, Li Q, Ai T, Wang L J Asthma Allergy. 2025; 18:391-402.
PMID: 40070491 PMC: 11895688. DOI: 10.2147/JAA.S507446.
Mou T, Wang Y, Fu Y, Wang Y, Li G BMC Pulm Med. 2024; 24(1):619.
PMID: 39696126 PMC: 11657815. DOI: 10.1186/s12890-024-03420-z.
Chen Z, Ma J, Lei J, Li Y, Zhao R, Zhao L J Asthma Allergy. 2024; 17:1001-1014.
PMID: 39411426 PMC: 11476322. DOI: 10.2147/JAA.S479215.
Long J, Jiang Y J Clin Med Res. 2024; 16(5):220-231.
PMID: 38855778 PMC: 11161183. DOI: 10.14740/jocmr5158.
Almeshari M, Alobaidi N, Sapey E, Stockley R, Stockley J Heliyon. 2023; 9(10):e20744.
PMID: 37867812 PMC: 10585212. DOI: 10.1016/j.heliyon.2023.e20744.